Pharmacies prove overcharges by matching wholesaler invoices to expert estimates of competitive prices. The overcharge is the gap between what the pharmacy paid and that competitive, or but-for, price. The federal case is In re Generic Pharmaceuticals Pricing Antitrust Litigation, No.
16-MD-2724 in Pennsylvania. According to the U.S. District Court filing via GovInfo, the plaintiffs allege manufacturers fixed prices, rigged bids and divided customers for more than 200 generic drugs court filing via GovInfo.
Official resources:
- Read the official notice from Govinfo — Use this primary source to verify the official announcement.
- Read the official guidance from Justice — Use this primary source to verify the official guidance.
Table of Contents
- Which pharmacies can claim as resellers?
- What purchase records prove payment?
- How do economists calculate the but-for price?
- What settlement money is in claims now?
- Where do pharmacy claims fail?
Which pharmacies can claim as resellers?
Pharmacies claim as Indirect Resellers when they bought generics from a wholesaler and resold them to patients. The group includes independent pharmacies, hospitals and clinics. Pharmaceutical Executive reports that qualifying purchases came through wholesalers such as AmerisourceBergen, Cardinal, McKesson and Morris and Dickson.
The pharmacy must show it paid the inflated price and then dispensed the drug. Direct buyers from manufacturers sit in a different track. This article covers only the reseller path.
What purchase records prove payment?
Proof starts with contemporaneous business records. Fine Kaplan and Black identifies wholesaler invoices and pharmacy account statements as the core evidence. Those records must cover May 1, 2009 to Dec.
31, 2019 for the current end-payer settlements. Each record should tie together five fields: Gaps matter. A missing year, supplier change, or incomplete archive can shrink the payable units for that pharmacy.
- drug name and strength
- quantity purchased
- purchase date
- price paid
- wholesaler or supplier name
How do economists calculate the but-for price?
An invoice shows what a pharmacy paid. It does not show what the price would have been without collusion. Economists build that second number.
According to the August 2026 federal court opinion, experts use manufacturer IQVIA MIDAS data, compare subject drugs to control drugs, and run regressions on price differences over defined conspiracy start and end dates August 2026 court opinion. The control drugs help isolate normal price movement from alleged conspiracy effects. The overcharge per unit is actual price minus but-for price. Multiplied by qualifying units, it becomes the damages figure.
What settlement money is in claims now?
The Justice Department separately resolved criminal charges against Teva and Glenmark through deferred prosecution agreements. Teva paid a $225 million penalty plus $50 million in drug donations, while Glenmark paid $30 million, with both divesting pravastatin lines for 2013-2015 conduct. For buyers, Fine Kaplan and Black announced that end-payer settlements now total $533 million, including $275 million from Sandoz and Fougera and $200 million from Sun and Taro, with claim forms due Nov.
9, 2026 claims announcement from Fine Kaplan and Black. Pharmaceutical Executive also reports Sandoz agreed to pay $28.5 million to resolve indirect-reseller pharmacy claims, subject to approvals, alongside larger state payments. Pharmacy filers should confirm which fund matches their purchases. State, end-payer and reseller settlements have different classes, periods and administrators.
Where do pharmacy claims fail?
The largest risk is defendant-specific proof. A broad price-fixing allegation does not prove every defendant joined every drug conspiracy. Chief Judge Michael Shea dismissed Pfizer and Greenstone because states did not show conspiracy on six products from 2010 to 2014, as reported by PM360 citing Reuters.
Pharmacies face the same issue when invoices name a drug but the evidence does not tie that maker to that drug. Pass-through is the second limit. Resellers must show the overcharge reached them and was not absorbed upstream. Missing invoices for a drug or year leave that portion unrecoverable.